Trial Profile
Phase 1, Open-label, Parallel Group, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AAI101 With Cefepime in Subjects With Varying Degrees of Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Cefepime/enmetazobactam-Allecra-Therapeutics (Primary)
- Indications Gram-negative infections; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors Allecra Therapeutics
- 27 Jun 2022 Status changed from recruiting to completed.
- 27 Sep 2018 New trial record